Enzo Biochem, Inc. ENZ
At closeApr 17, 2025, 4:00 PM EDT
52-week range unavailable
- YTD
- -56.07%
- 1 year
- -72.71%
- Market cap
- 38.71M
- Revenue (ttm)
- 31.91M
- Profit margin
- -81.73%
- Shares out
- 52.24M
- Forward P/E
- -1.90
- Dividend
- 0.40 (39.60%)
- Ex-dividend date
- Nov 14, 2024
- YTD return
- -56.07%
- 1-year return
- -72.71%
- Volume
- 4.12M
- Open
- 0.3702
- Previous close
- 0.3138
- Day's range
- 0.3138 – 0.40
- Beta
- 0.73
- Earnings date
- Nov 4, 2024
YTD -0.3251 (-45.15%)
Key statistics
- Enterprise value
- 3.90M
- PEG ratio
- 0.00
- Price / sales
- 1.21
- Price / book
- 0.69
- Dividend yield
- 39.60%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -18.95M
- Total cash
- 52.37M
- Total debt
- 3.51M
- Return on equity
- -14.59%
- Short % of float
- 0.90%
- 50-day average
- 1.06
- 200-day average
- 1.12
Next earnings
Nov 4, 2024
Expected Nov 4, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Dec 16, 2024 | Oct 1, 2024 | 0.00 | -0.05 | — | — |
| Nov 4, 2024 | Jul 1, 2024 | 0.00 | — | — | — |
| Jun 13, 2024 | Apr 1, 2024 | 0.00 | -0.03 | — | — |
| Mar 13, 2024 | Jan 1, 2024 | 0.00 | 0.00 | — | — |
| Dec 15, 2023 | Oct 1, 2023 | 0.00 | -0.11 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 4, 2014 | Craig-Hallum | init | — | Buy |
| Jul 2, 2013 | Sidoti & Co. | init | — | Neutral |
About Enzo Biochem, Inc.
Enzo Biochem, Inc., a life sciences company, engages in the labeling and detection technologies from DNA to whole cell analysis in the United States and internationally. The company offers labels, dyes, antibodies, genomic probes, immunoassays, biochemicals, and proteins are used to label, detect, and visualize a biological target of interest in drug discovery exploration and drug development process development. Its proprietary products and technologies play roles in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry. The company licenses its technology. It serves academic researchers, clinical researchers, biotechnology and pharmaceutical companies, and diagnostic manufacturers. Enzo Biochem, Inc. was incorporated in 1976 and is headquartered in Farmingdale, New York.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- United States
- Website
- enzo.com
News
Enzo Biochem, Inc. To be Acquired by Battery Ventures in All-Cash Transaction 
Enzo Biochem Reports Third Quarter Fiscal Year 2025 Results 
Enzo Biochem, Inc. Announces Review of Strategic Alternatives after Receiving Multiple Inquiries Regarding a Potential Transaction 
The Zacks Analyst Blog AbbVie, The TJX, The Charles Schwab, Enzo Biochem and CVD Equipment 
Why Argenx Shares Are Trading Higher By 5%; Here Are 20 Stocks Moving Premarket 
12 Health Care Stocks Moving In Wednesday's Pre-Market Session 
12 Health Care Stocks Moving In Monday's After-Market Session 
Why Xos Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket 
12 Health Care Stocks Moving In Friday's After-Market Session 
Enzo Biochem Announces Notification to New York Stock Exchange of Intention to Voluntarily Delist Common Stock and Transfer Trading of Shares to OTCQX
Your note
Sign in to keep a note on ENZ — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CANNON KARA | Chief Executive Officer | Stock Award(Grant) | Feb 22, 2024 | 496,362 |
| PULLY STEVEN J | Director | Stock Award(Grant) | Jan 30, 2024 | 97,095 |
| RADOFF BRADLEY LOUIS | Director | Stock Award(Grant) | Jan 30, 2024 | 4,820,880 |
| TAGLIAFERRI MARY ANN | Director | Stock Award(Grant) | Jan 30, 2024 | 312,383 |
| WALTERS IAN B. | Director | Stock Award(Grant) | Feb 12, 2023 | 155,917 |
| WOLF JAMES G | Beneficial Owner of more than 10% of a Class of Security | Purchase | Feb 12, 2023 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Harbert Fund Advisors, Inc. | 9.91% | 5,175,913 | 3.84M | Sep 29, 2024 |
| Renaissance Technologies, LLC | 4.84% | 2,527,529 | 1.87M | Sep 29, 2024 |
| Vanguard Group Inc | 3.59% | 1,876,622 | 1.39M | Sep 29, 2024 |
| Blackrock Inc. | 1.84% | 959,151 | 710.73K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.71% | 368,646 | 273.17K | Sep 29, 2024 |
| Dimensional Fund Advisors LP | 0.58% | 304,492 | 225.63K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.27% | 1,187,908 | 880.24K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.18% | 618,881 | 458.59K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.41% | 216,370 | 160.33K | Oct 30, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.34% | 175,200 | 129.82K | Sep 29, 2024 |
| iShares Micro Cap ETF | 0.19% | 99,803 | 73.95K | Oct 30, 2024 |
| Dimensional ETF Tr-Dimensional U.S. Targeted Value ETF | 0.16% | 82,649 | 61.24K | Jul 30, 2024 |